VK2735 is a glp-1 / gip agonist used for weight loss. VK2735 is a dual GLP-1 and GIP agonist, the same two-receptor family as tirzepatide. In plain terms: it works on two appetite-and-blood-sugar signals for weight loss, with promising early results. It is in trials as both a shot and a pill.

How much water do I add to VK2735?

You can reconstitute VK2735 with 0.5, 1, or 2 mL of bacteriostatic water. Each option produces a different concentration and syringe draw for the same dose. Use the calculator to see which is easiest to measure.

What does VK2735 cost per dose?

Cost per dose depends on vial size, price paid, and your dose. Enter your vendor's price in the VK2735 calculator to see cost per dose and monthly cost.

What is the reference dose for VK2735?

The commonly referenced range is 2.5 up to 15 mg per week (start low, increase slowly), taken weekly. This is reference information, not a recommendation. Talk to a licensed clinician.

What are the side effects of VK2735?

Reported side effects of VK2735 include: Stomach side effects.; Trial-only.. Severity and frequency vary by person and dose.

Who should not take VK2735?

VK2735 is generally not appropriate for: No formal contraindications established; Pregnancy. Talk to a licensed clinician before starting.

New?New to peptides?Start here →

Decoding

VK2735_Dosage, benefits & legal status

By the Peptide Decoding Editorial Team

Published July 22, 2026 · Updated July 25, 2026

An experimental weight-loss compound in the tirzepatide family, as a shot or pill.

Weight lossGLP-1 / GIP agonistInvestigational

InGLP-1 agonists

Common vial size10 mg

Dose2.5 up to 15 mg per week (start low, increase slowly)

FrequencyWeekly

RouteUnder the skin, or by mouth

StatusInvestigational

MixYour choice, calculate it

CycledNot cycled in the trials

Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.

What is VK2735?

Plain language first. The technical label stays, but it never stands alone.

Overview

It works on two appetite-and-blood-sugar signals for weight loss, with promising early results. It is in trials as both a shot and a pill.

The technical version

VK2735 is a dual GLP-1 and GIP agonist, the same two-receptor family as tirzepatide.

What it's used for

An experimental weekly (and oral) weight-loss compound in the same family as tirzepatide, with promising early results.

How does VK2735 work?

What it does in the body, and where.

VK2735 targets the same two receptors as tirzepatide, GLP-1 and GIP. It is being developed as both an injection and a pill.

01
GLP-1 and GIP together
The receptor pair that produced the largest approved weight-loss results so far.
02
An oral version is in trials too
Most peptides cannot survive digestion. If the tablet works, it removes the injection barrier that keeps many people away from this class.
03
Still investigational
Phase 2 results are promising and phase 3 is running. Nothing here is approved.

Receptors

Hits 2 receptors at once.

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

Weight loss, as either a pill or an injectionInvestigational

The published record

Research index

Records indexed for VK2735

6 in humans, 1 of them original studies.

5 registered trials, 0 with posted results.

Browse the records

In animalsPro

In the labPro

ReviewsPro

Senior author sharePro

Counted from Europe PMC indexing, not read by a person. Human means indexed under humans, which includes reviews and work on human cells. Original studies exclude reviews and lab work on human cells.Last updated 11 September 2026.

Compound field notes

At a glance

Four things to know about VK2735

Evidence

Investigational

How much, and do you cycle it?

The range, and whether you take breaks.

2.5 up to 15 mg per week (start low, increase slowly), weekly. Not cycled in the trialsTrial dose

Given continuously for the whole study period: VANQUISH-1, 78 weeks. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break.

Compare this against the whole library →

How long does it stay in the body?

The half-life, and where the figure comes from.

170 to 250 hoursTrial protocol

From a company disclosure rather than a full pharmacokinetic paper. The oral formulation is a separate product with its own profile.

Source: Viking Therapeutics phase 1 disclosure, 28 March 2023. Phase 2 VENTURE, Obesity 2026, DOI 10.1002/oby.70106

You can compare this against the whole library to see where it sits.

How do I dose and price it?

Enter your vial and your dose. Pick a mix. We show the draw and the cost.

The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.

Your vial size (mg)

Printed on the vial.

What you paid per vial

Used for cost per dose only.

Your dose (mg)

Commonly referenced range: 2.5 up to 15 mg per week (start low, increase slowly)Trial dose

Choose your mix

0.5 mL water13units · 20 mg/mL

Half a 100-unit syringe

1 mL water25units · 10 mg/mL

One full 100-unit syringe

Easiest

2 mL water50units · 5 mg/mL

Two full 100-unit syringes

your own mL

units · —

Enter your own volume

Measuring the water1 mL = one full 100-unit syringe.

Your draw

50 / 100 units

Full calculator with reorder date →Read a syringe →

How do you store it?

Before mixing, and after.

Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.

Unmixed lyophilized VK2735 keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.

What are the side effects and cautions?

Known cautions and warnings for this compound.

Who should avoid it

Check these before anything else.

No formal contraindications established
Pregnancy

Stop and get help

These are emergencies. Seek care.

Vomiting badly enough that you cannot keep fluids down
Signs of an allergic reaction such as face or throat swelling, hives, or trouble breathing

Common effects

Expected, and usually mild.

Nausea in roughly 43 to 58% depending on the form
Vomiting in roughly 18 to 26%
At the highest oral dose, 38% stopped because of stomach effects

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

Is VK2735 approved?

And where the numbers on this page come from.

No. VK2735 is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.

Approval status
Investigational
Route
Under the skin, or by mouth
Checked
September 2026

What has happened recently

We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.

You can compare this against the whole library, or read how to check a seller.

DoseFrom published clinical trials. Not approved by a regulator for this dose.
Vial sizeFrom what vendors typically list; not a recommendation.
Sources
Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, for weight management: phase 2, randomized, 13-week VENTURE study, Obesity Viking Therapeutics, phase 2 VENTURE-Oral dosing data presented at the European Congress on Obesity
Reviewed8 September 2026

What else is like VK2735?

Others in GLP-1 agonists, side by side.

If you're weighing VK2735, it's worth reading Orforglipron, CagriSema, and Danuglipron in the same class.

YOU ARE HERE

VK2735

An experimental weight-loss compound in the tirzepatide family, as a shot or pill.

Investigational

Dose: 2.5 up to 15 mg per week (start low, increase slowly)
How often: Weekly

ORFO

Orforglipron

The first GLP-1 weight-loss pill, approved in 2026 and taken any time of day.

FDA-approved

Dose: 0.8 up to 17.2 mg per day (six steps, 30 days apart)
How often: Daily

CAGSEM

CagriSema

A weekly two-in-one shot combining cagrilintide and semaglutide for bigger loss.

Investigational

Dose: 2.4 mg per week
How often: Weekly

DANU

Danuglipron

An experimental weight-loss pill whose development was stopped over a liver-injury signal.

Investigational

Dose: 40 up to 200 mg per dose
How often: Daily

See other GLP-1 receptor drugs

How this stacks up against other GLP-1 drugs

Guides for this compound

How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.

Sources

Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, for weight management: phase 2, randomized, 13-week VENTURE study, Obesity(2026)
Peer-reviewed publication of the subcutaneous phase 2. Mean weight reduction ran from 9.2 kg at 2.5 mg to 14.6 kg at 15 mg, or 9.1 to 14.7 percent, against 1.8 kg and 1.7 percent on placebo. People with diabetes were excluded. Thirteen weeks is a short window.
Viking Therapeutics, phase 2 VENTURE-Oral dosing data presented at the European Congress on Obesity(2026)
The oral tablet arm. Mean change from baseline ran from -1.3 kg on placebo to -12.1 kg at 120 mg, with 80 percent of that cohort reaching 10 percent weight loss against 5 percent on placebo. Oral and subcutaneous are separate formulations with separate data.

Last reviewed 8 September 2026

Beyond these, 6 records are indexed. Browse the records